Title : Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

Pub. Date : 2013 Aug

PMID : 23792568






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We report a case of a patient with BRAF-mutant metastatic colon cancer whose disease had progressed on FOLFOX plus bevacizumab and subsequent FOLFIRI plus cetuximab. FOLFIRI regimen B-Raf proto-oncogene, serine/threonine kinase Homo sapiens